Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Catanzaro – page 8

126 clinical trials in Catanzaro, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Catanzaro at a glance
126
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

126 trials in Catanzaro

Open in trial search

Plasma cell myeloma

Not recruiting

Study on Carfilzomib, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Transplant

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carfilzomib
  • Sponsor:Universita' Degli Studi Di Torino

Colorectal cancer metastatic

Not recruiting

Study on Cetuximab-Based Treatment for Metastatic Colorectal Cancer in Patients with RAS/BRAF Wild Type Tumors

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Gruppo Oncologico Dell'Italia Meridionale

Back pain

Not recruiting

Study on the Effectiveness of Diclofenac Sodium and Thiocolchicoside in Relieving Acute Low Back Pain in Adults

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Diclofenac
  • Sponsor:Epifarma S.r.l.

Acute myeloid leukaemia

Not recruiting

Study of venetoclax with fludarabine, cytarabine and idarubicin combination therapy in newly diagnosed patients with intermediate or high-risk Acute Myeloid Leukemia

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cytarabine
  • Sponsor:Fondazione Gimema Franco Mandelli Onlus

Type 2 diabetes mellitus+1

Not recruiting

Study comparing semaglutide with insulin glargine in overweight adults with type 2 diabetes: effectiveness of combined treatment versus insulin alone

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Insulin Glargine
  • Sponsor:Novo Nordisk A/S

Neoplasm+2

Not recruiting

Study of ELVN-002 with Trastuzumab and Chemotherapy for Patients with Advanced HER2+ Solid Tumors, Colorectal Cancer, and Breast Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Enliven Therapeutics Inc.

Juvenile idiopathic arthritis

Not recruiting

Study on the Safety and Effectiveness of Adalimumab and Etanercept in Children with Active Juvenile Idiopathic Arthritis

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Adalimumab
  • Sponsor:Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico

K-ras gene mutation+2

Not recruiting

Study Comparing Divarasib, Sotorasib, and Adagrasib for Patients with Advanced or Metastatic KRAS G12C-Positive Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Sponsor:F. Hoffmann-La Roche AG

Partial seizures

Not recruiting

Study on the Safety and Effectiveness of Azetukalner for Adults with Focal Epilepsy Taking 1 to 3 Anti-Seizure Medications

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Azetukalner
  • Sponsor:Xenon Pharmaceuticals Inc.

Partial seizures

Not recruiting

Study on the Effectiveness and Safety of BHV-7000 for Adults with Refractory Focal Onset Epilepsy

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:BHV-7000
  • Sponsor:Biohaven Therapeutics Ltd.

Crohn's disease

Not recruiting

Study on the Effects of Etrasimod Arginine for Patients with Moderate to Severe Crohn's Disease

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Etrasimod Arginine
  • Sponsor:Arena Pharmaceuticals Inc.

Neovascular age-related macular degeneration

Not recruiting

Study on the Effectiveness of OPT-302 and Ranibizumab for Patients with Wet Age-related Macular Degeneration

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Ranibizumab
  • Sponsor:Opthea Limited

Other cities in Italy

The busiest research cities in the country

All 237 cities in Italy

Clinical research in Catanzaro

What the registry says about research in the country

01 Oncology Research

Clinical investigations focusing on innovative treatments for various cancers, including colorectal cancer, ovarian cancer, and breast cancer. Studies evaluate targeted therapies and maintenance treatments to improve patient outcomes.

  • Metastatic Colorectal Cancer Treatment
  • Advanced Ovarian Cancer Therapies
  • Triple-Negative Breast Cancer Management

Particular emphasis on biomarker-driven treatment approaches and personalized medicine strategies.

02 Inflammatory Conditions

Studies examining new therapeutic options for inflammatory bowel diseases, with trials targeting Crohn's Disease and Ulcerative Colitis. Research focuses on novel biological treatments and long-term disease management.

  • Inflammatory Bowel Disease Therapies
  • Chronic Disease Management
  • Novel Biological Treatments

Emphasis on developing treatments for patients with inadequate response to conventional therapies.

03 Metabolic Disorders

Research initiatives addressing Type 2 Diabetes, obesity, and related metabolic conditions. Studies evaluate new medications for weight management and cardiovascular outcomes in diabetic patients.

  • Diabetes Management
  • Weight Control Therapies
  • Cardiovascular Risk Reduction

Focus on innovative therapeutic approaches and long-term disease control strategies.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.